Elective uterine preservation: a novel concept to tackle reproductive ageing. Fertility preservation beyond ovaries
review
OA: closed
CC0
AI-generated summary
This paper introduces the concept of elective uterine preservation alongside ovarian preservation to address reproductive aging, proposing GnRH antagonists as a potential therapy to stabilize the uterus and slow its aging process.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
With a growing number of women in developed countries having children later in life, it is time to rethink women's reproductive health. This trend of 'delayed parenthood' reflects a complex interplay of labour market rules, personal choices, rarefying social connections and the renowned possibilities of assisted reproductive technology (ART). While ART offers support, its success wanes with age, prompting a rise in additional strategies such as elective ovarian cryopreservation. However, the healthy ageing of the uterus is equally vital and often under-considered. Highly prevalent conditions such as leiomyomas and adenomyosis threaten fertility and can compromise or worsen physiological uterine ageing. The idea that the uterus can be surgically repaired any time or multiple times is a blind strategy that eventually wastes uterine reproductive potential. Oral gonadotrophin-releasing hormone (GnRH) antagonists with add-back therapy are a promising strategy for stabilizing the uterus while controlling symptoms of hormonally driven conditions, in long-term regimens (104 weeks' follow-up) as well. 'Uterine freezing' is a novel concept to delay uterine ageing and possibly preserve uterine reproductive potential. This article calls for a holistic approach that values both ovarian and uterine preservation strategies, encouraging healthcare providers to empower women in managing their fertility and support their complex journeys toward motherhood.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
- Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study 2024
- Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3) 2024
- Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix 2023
References (9)
- Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3) via openalex
- Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix via openalex
- Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study via openalex
- W4362666252 via openalex
- W2045833234 via openalex
- W4319601707 via openalex
- W4387701118 via openalex
- W3129366643 via openalex
- W4386388659 via openalex
Source provenance
- europepmc
- last seen: 2026-06-18T06:15:08.409253+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-06-18T06:12:04.812000+00:00
- unpaywall
- last seen: 2026-06-18T06:36:33.011116+00:00
License: CC0
· commercial use OK